Loading...
Peptides targeting metabolism, weight management, and body composition. Research in this category includes compounds affecting appetite regulation, fat oxidation, and metabolic rate.
A modified fragment of human growth hormone specifically researched for its fat-metabolising properties without the growth-promoting effects of full HGH.
View detailsA GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
View detailsA triple monoamine reuptake inhibitor originally developed for neurological conditions, now researched for its potent effects on appetite suppression and weight loss.
View detailsA fragment of human growth hormone corresponding to amino acids 176-191, researched specifically for its fat-metabolising properties.
View detailsA naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
View detailsA modified fragment of human growth hormone targeting fat metabolism without the growth-promoting effects of full HGH.
View detailsA novel triple monoamine reuptake inhibitor originally developed for neurological disorders, now researched primarily for obesity treatment.
View detailsA natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
View detailsThe 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
View detailsA pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
View detailsA hormone produced by fat cells that regulates appetite, energy expenditure, and body weight.
View detailsA dual glucagon/GLP-1 receptor agonist under development by Boehringer Ingelheim, researched for its potential in weight management, metabolic health, and non-alcoholic steatohepatitis (NASH).
View detailsA long-acting amylin analogue developed by Novo Nordisk, researched for its role in appetite regulation, satiety signalling, and weight management, including as part of the CagriSema combination with semaglutide.
View detailsMonograph coming soon.
Monograph coming soon.
Monograph coming soon.